JP2007502327A5 - - Google Patents

Download PDF

Info

Publication number
JP2007502327A5
JP2007502327A5 JP2006533113A JP2006533113A JP2007502327A5 JP 2007502327 A5 JP2007502327 A5 JP 2007502327A5 JP 2006533113 A JP2006533113 A JP 2006533113A JP 2006533113 A JP2006533113 A JP 2006533113A JP 2007502327 A5 JP2007502327 A5 JP 2007502327A5
Authority
JP
Japan
Prior art keywords
formulation
antagonist
formulation according
tnf
highly specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006533113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502327A (ja
Filing date
Publication date
Priority claimed from US10/456,948 external-priority patent/US7344716B2/en
Priority claimed from US10/610,355 external-priority patent/US7429378B2/en
Priority claimed from US10/631,487 external-priority patent/US20040229878A1/en
Priority claimed from US10/640,412 external-priority patent/US7553827B2/en
Application filed filed Critical
Priority claimed from PCT/US2004/015285 external-priority patent/WO2005000283A2/en
Publication of JP2007502327A publication Critical patent/JP2007502327A/ja
Publication of JP2007502327A5 publication Critical patent/JP2007502327A5/ja
Pending legal-status Critical Current

Links

JP2006533113A 2003-05-13 2004-05-13 椎間板変性症の治療法 Pending JP2007502327A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47009803P 2003-05-13 2003-05-13
US10/456,948 US7344716B2 (en) 2003-05-13 2003-06-06 Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US10/610,355 US7429378B2 (en) 2003-05-13 2003-06-30 Transdiscal administration of high affinity anti-MMP inhibitors
US10/631,487 US20040229878A1 (en) 2003-05-13 2003-07-31 Transdiscal administration of specific inhibitors of P38 kinase
US10/640,412 US7553827B2 (en) 2003-08-13 2003-08-13 Transdiscal administration of cycline compounds
PCT/US2004/015285 WO2005000283A2 (en) 2003-05-13 2004-05-13 A method of treating degenerative disc disease

Publications (2)

Publication Number Publication Date
JP2007502327A JP2007502327A (ja) 2007-02-08
JP2007502327A5 true JP2007502327A5 (enExample) 2007-06-28

Family

ID=33556747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006533113A Pending JP2007502327A (ja) 2003-05-13 2004-05-13 椎間板変性症の治療法

Country Status (8)

Country Link
EP (2) EP2286804A1 (enExample)
JP (1) JP2007502327A (enExample)
KR (1) KR20060014048A (enExample)
AU (1) AU2004251042A1 (enExample)
BR (1) BRPI0410331A (enExample)
CA (1) CA2525928A1 (enExample)
MX (1) MXPA05012275A (enExample)
WO (1) WO2005000283A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US20040054414A1 (en) 2002-09-18 2004-03-18 Trieu Hai H. Collagen-based materials and methods for augmenting intervertebral discs
JP2006515765A (ja) 2002-11-15 2006-06-08 エスディージーアイ・ホールディングス・インコーポレーテッド 滑膜性関節を治療するためのコラーゲンベース材料および方法
US7344716B2 (en) 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
US7553827B2 (en) 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US8273347B2 (en) 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
US8361467B2 (en) 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US20050100538A1 (en) * 2003-07-31 2005-05-12 Attawia Mohamed Intradiscal injection of anti-oxidants
US8895540B2 (en) 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
US20070043118A1 (en) * 2005-08-16 2007-02-22 Discogen, Llc Method of treating a subject suffering from degenerative disc disease using a nitric oxide synthase inhibitor
CA2623648C (en) 2005-09-21 2018-05-22 The Regents Of The University Of California Systems, compositions, and methods for local imaging and treatment of pain
WO2007098099A2 (en) * 2006-02-16 2007-08-30 Discogen, Llc Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US8986696B2 (en) 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
EP3085699B1 (en) 2008-07-31 2022-03-02 Firmenich Incorporated Processes for making sweet taste enhancers
WO2017176196A1 (en) * 2016-04-04 2017-10-12 Chalmers Ventures Ab Methods and compositions for the treatment of intervertebral disc herniation
WO2019060869A1 (en) * 2017-09-25 2019-03-28 Discitisdx, Inc. METHODS FOR TREATING DEGENERATIVE DISC DISEASE AND CHRONIC LOMBALGIA
US11911504B2 (en) * 2018-02-02 2024-02-27 Galen Therapeutics Llc Apparatus and method for protecting neurons and reducing inflammation and scarring
WO2020033420A1 (en) 2018-08-07 2020-02-13 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
CN110613837A (zh) * 2019-10-24 2019-12-27 内蒙古医科大学第二附属医院 TGF-β在制备预防或治疗腰椎间盘突出药物中的应用
CN117106900A (zh) * 2023-09-27 2023-11-24 上海长征医院 一种适用于椎间盘退变预防和诊疗的分子标志物ace2及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
EP0288088B1 (en) 1987-04-24 1994-03-09 Teijin Limited Detection of tumor necrosis factor; monoclonal antibody and kit
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0486526B2 (en) 1989-08-07 2001-03-07 Peptech Limited Tumour necrosis factor binding ligands
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5270300A (en) 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
DE69720190T2 (de) 1996-02-02 2003-12-11 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
US7115557B2 (en) 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US20010006948A1 (en) * 1998-11-25 2001-07-05 James D. Kang Gene transfer to intervertebral disc cells
US6537549B2 (en) * 1999-02-24 2003-03-25 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
US6015557A (en) * 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
US6419944B2 (en) 1999-02-24 2002-07-16 Edward L. Tobinick Cytokine antagonists for the treatment of localized disorders
US6428576B1 (en) * 1999-04-16 2002-08-06 Endospine, Ltd. System for repairing inter-vertebral discs
US6352557B1 (en) 1999-08-13 2002-03-05 Bret A. Ferree Treating degenerative disc disease through transplantion of extracellular nucleus pulposus matrix and autograft nucleus pulposus cells
US6541477B2 (en) 1999-08-27 2003-04-01 Scios, Inc. Inhibitors of p38-a kinase
US20020032155A1 (en) * 2000-06-30 2002-03-14 Ferree Bret A. Method of treating disc herniation and disc degeneration with concentrated growth and differentiation factors
US20020026244A1 (en) 2000-08-30 2002-02-28 Trieu Hai H. Intervertebral disc nucleus implants and methods
NZ526624A (en) 2000-12-22 2005-07-29 Ortho Mcneil Pharm Inc Substituted triazole diamine derivatives as kinase inhibitors
SE0102067D0 (sv) 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
JP2004535434A (ja) 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化

Similar Documents

Publication Publication Date Title
Kay et al. The role of interleukin-1 in the pathogenesis of rheumatoid arthritis
Mundy Osteoporosis and inflammation
Zou et al. Tumor necrosis factor‐α mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism
Miljkovic et al. Inducible nitric oxide synthase activation by interleukin-17
Kirkwood et al. Novel host response therapeutic approaches to treat periodontal diseases
Esteban et al. Effect of simultaneous blockade of AT1 and AT2 receptors on the NFκB pathway and renal inflammatory response
Hofbauer et al. The role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
Bluthé et al. Central mediation of the effects of interleukin-1 on social exploration and body weight in mice
Koenen et al. Glucocorticoid receptor in stromal cells is essential for glucocorticoid-mediated suppression of inflammation in arthritis
WinZen et al. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1
Tracey et al. Tumor necrosis factor and regulation of metabolism in infection: role of systemic versus tissue levels
JP2007500723A5 (enExample)
Ando et al. Imatinib mesylate inhibits osteoclastogenesis and joint destruction in rats with collagen-induced arthritis (CIA)
WO2002096461A1 (en) Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
CA2182723A1 (en) The use of anti-tnf antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
JP2009507838A5 (enExample)
US20230406918A1 (en) Method of treatment of a tumor with il-8 antibody
JP2005525352A5 (enExample)
Grounds et al. Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice
Ito Anti-interleukin-6 therapy for Crohn's disease
AU2004251042A1 (en) A method of treating degenerative disc disease
Hanifin Atopic dermatitis: new therapeutic considerations
Roodman Treatment strategies for bone disease
SK287522B6 (sk) Použitie inhibítorov produkcie a/alebo účinku IL-18
Lin et al. The renoprotective potential of pentoxifylline in chronic kidney disease